SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections.
Scynexis stock last closed at $3.77, down 2.33% from the previous day, and has decreased 31.4% in one year. It has overperformed other stocks in the Drug Manufacturers - Specialty & Generic industry by 0.69 percentage points. Scynexis stock is currently +6.8% from its 52-week low of $3.53, and -58.66% from its 52-week high of $9.12.
As of Oct 30, 2026, there are 9.95M SCYX shares outstanding. The market capitalization of SCYX is $37.51M. In the last 24 hours, 118,000 SCYX shares were traded.
You need a brokerage account to access the NASDAQ market and buy SCYX shares.
We believe that eToro is the best place to buy stocks. eToro gives you:
Get $10 towards your purchase of shares by creating an account with eToro now. This offer is only for US users.
Open eToro AccountNow that you've selected the best brokerage, you need to fill out some personal information so you are able to buy SCYX stock today.
Now that you have finished signing up on the best stock app, your next step is to transfer the money for your investment:
Check out the video below for more details transferring money into your investment account.
Once you have figured out the best place to buy Scynexis stock, it's absolutely critical to evaluate their stock before you invest, so you truly understand the risk and upside.
WallStreetZen was designed to help part-time investors perform more in-depth fundamental analysis in less time.
You can view all of the due diligence checks on SCYX's stock page.
You can use many financial metrics, analyses, models, and charts to gauge SCYX's intrinsic value.
Using relative valuations methods:
You can do more valuation research on SCYX's stock here.
Out of 1 Equities analysts who give ratings on SCYX, the consensus analyst rating on SCYX is a Strong Buy
Please keep in mind that analyst ratings are not stock recommendations, nor are they financial advice.
You can dive deeper into what analysts are saying on the Scynexis stock forecast page.
Last year, SCYX revenue was $19.22M. Over the last five year, SCYX's revenue has increased by 9.78% per year. This was faster than the Drug Manufacturers - Specialty & Generic industry average of 8.12%.
Learn more about SCYX's earnings and revenue performance here.
Over the past 12 months, insiders at SCYX have not bought or sold any shares.
Learn more about who owns SCYX shares here.
No, Scynexis doesn't provide an income stream by paying out dividends.
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other community members have to say.
You have two main order types:
Click the Open button and your broker will place the order.
If you want more assistance investing in stocks on eToro, watch the how to video below:
Now that you own some SCYX stock, you'll want to stay up-to-date on your new investment.
Start a watchlist to track the latest developments regarding your SCYX stock.
To reiterate, here are the 6 steps for buying Scynexis stock:
If you are looking for a brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you want to keep an eye on your new investment in Scynexis, add SCYX to your watchlist below.